Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The treatment of type 2 diabetes places a significant economic burden on the U.S. healthcare system. Given the intense competition among antidiabetic therapies, the type 2 diabetes access and reimbursement space is both extremely dynamic and highly influential on treatment patterns. Branded therapies experience high rates of prescribing restrictions as payers steer prescriptions toward drugs with lower prices. Manufacturers of agents such as SGLT-2 inhibitors, GLP-1 receptor agonists, and insulins need to skillfully navigate contract agreements/rebates with payers to gain favorable formulary coverage.
Already a Client? Log in to access this report.
Surbhi Gupta is an Insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group and has worked on contents on pulmonary hypertension and obesity. She completed her Masters with specialization in Pharmacology, and a Bachelor's degree in Pharmacy from the University Of Delhi. Before joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve, where she was involved in competitive intelligence projects across multiple indications (such as atrial fibrillation, ACS, VTE, renal anemia, and several oncology indications). She also worked as a Medical writer at the clinical research organization, Apcer Pharma.